

# iREVIEWS

STATE-OF-THE-ART PAPER

## Left Ventricular Remodeling in Heart Failure

### Current Concepts in Clinical Significance and Assessment

Marvin A. Konstam, MD, Daniel G. Kramer, MD, Ayan R. Patel, MD,  
Martin S. Maron, MD, James E. Udelson, MD

*Boston, Massachusetts*

Ventricular remodeling, first described in animal models of left ventricular (LV) stress and injury, occurs progressively in untreated patients after large myocardial infarction and in those with dilated forms of cardiomyopathy. The gross pathologic changes of increased LV volume and perturbation in the normal elliptical LV chamber configuration is driven, on a histologic level, by myocyte hypertrophy and apoptosis and by increased interstitial collagen. Each of the techniques used for tracking this process—echocardiography, radionuclide ventriculography, and cardiac magnetic resonance—carries advantages and disadvantages. Numerous investigations have demonstrated the value of LV volume measurement at a single time-point and over time in predicting clinical outcomes in patients with heart failure and in those after myocardial infarction. The structural pattern of LV remodeling and evidence of scarring on cardiac magnetic resonance have additional prognostic value. Beyond the impact of abnormal cardiac structure on cardiovascular events, the relationship between LV remodeling and clinical outcomes is likely linked through common local and systemic factors driving vascular as well as myocardial pathology. As demonstrated by a recent meta-analysis of heart failure trials, LV volume stands out among surrogate markers as strongly correlating with the impact of a particular drug or device therapy on patient survival. These findings substantiate the importance of ventricular remodeling as central in the pathophysiology of advancing heart failure and support the role of measures of LV remodeling in the clinical investigation of novel heart failure treatments. (J Am Coll Cardiol Img 2011;4:98–108) © 2011 by the American College of Cardiology Foundation

#### **Mechanisms and Characteristics of Ventricular Remodeling**

The term *ventricular remodeling* refers to alteration in ventricular architecture, with associated increased volume and altered chamber configuration, driven on a histologic level by a combination of pathologic myocyte hypertrophy, myocyte apoptosis, myofibroblast prolifer-

ation, and interstitial fibrosis (1–3). Although originally described after myocardial infarction (MI), ventricular remodeling develops in response to a variety of forms of myocardial injury and increased wall stress (4,5).

Early work by Pfeffer and Braunwald (6) in a rodent MI model showed that a greater degree of myocardial injury was associated with a greater degree of chamber remodeling over

From the Cardiovascular Center, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts. Dr. Konstam has received research support and/or is a consultant for Otsuka, Merck, and Pfizer. Dr. Udelson has received research support and/or is a consultant for Otsuka, Merck, Pfizer, and Medtronic. All other authors report that they have no relationships to disclose.

Manuscript received August 6, 2010; revised manuscript received September 24, 2010, accepted October 4, 2010.

time. Since that time, multiple studies have substantiated the relationship between infarct size and the extent of left ventricular (LV) remodeling (3,7,8). Solomon et al. (9) showed that patients with larger MIs, as evidenced by greater elevations in serum creatine kinase concentrations, manifest greater 90-day increases in LV end-diastolic volume (EDV) and greater reductions in left ventricular ejection fraction (LVEF) (Fig. 1).

The initial post-MI phase of LV remodeling results from fibrotic repair of the necrotic area with scar formation, elongation, and thinning of the infarcted zone (Fig. 2). LV volumes increase, a response that is sometimes considered adaptive, associated with stroke volume augmentation and maintenance of normal cardiac output (10). However, beyond this early stage, the remodeling process is driven predominantly by hypertrophic myocyte elongation in the noninfarcted zone, resulting in increased wall mass, chamber enlargement, and a shift from an elliptical to a more spherical chamber configuration (3,11–13). These changes, together with a decline in performance of the pathologically hypertrophied myocyte and interstitial fibrosis within the noninfarcted zone, result in progressive decline in ventricular performance. Left unchecked, LV hypertrophy, dilation, and contractile dysfunction appear to advance indefinitely, regardless of the initial inciting cause, as evidenced by progressive increases in LV volumes (12,14,15).

Pathologic LV remodeling is closely linked to activation of a series of neuroendocrine, paracrine, and autocrine factors, which are up-regulated after myocardial injury and in the setting of increased LV wall stress and hemodynamic derangement. Contributing factors include the renin-angiotensin-aldosterone axis, the adrenergic nervous system, increased oxidative stress, proinflammatory cytokines, and endothelin. Renin-angiotensin system inhibition (14–18) and beta-adrenergic blockade (19–23) have each been shown to markedly attenuate or reverse LV remodeling in patients with heart failure and LV dilation, although aldosterone blockade has yielded mixed results (24,25), and findings with antagonists of endothelin (26) and vasopressin (27) have been disappointing.

With continued application of imaging techniques within populations of patients with MI and/or heart failure, there has been increased understanding of the various macroscopic patterns of LV remodeling and their relationship to underlying etiology and prognosis. Verma et al. (28), examining patients with heart failure and/or LVEF  $\leq$ 35%

after MI, in the VALIANT (VALsartan In Acute myocardial iNfarcTion) echocardiographic study, defined 3 patterns of LV remodeling based on measurement of the LV mass index (LVMI) and relative wall thickness (RWT): concentric remodeling (normal LV mass index LVMI and increased RWT), eccentric hypertrophy (increased LVMI and normal RWT), concentric hypertrophy (increased LVMI and increased RWT) (Fig. 3) (28). Each of these patterns was associated with a higher risk of subsequent cardiovascular events than that of normal LV morphology, with each of these 3 patterns carrying progressively worse prognosis (see the “Relationship between LV remodeling and prognosis in patients with heart failure and decreased LVEF” section).

### Techniques for Assessing Ventricular Remodeling


LVEF, the most common metric of cardiac performance in clinical practice, is influenced by the degree of LV remodeling more than by any other factor (29). Other, more precise metrics of remodeling, such as LV volumes and mass, have received greater focus in clinical trials than in clinical practice (30), yet these measurements relate more closely to prognosis and to the impact of therapy than does LVEF. For example, White et al. (31) demonstrated that within groups with various degrees of post-MI LV dysfunction defined by LVEF, analysis of LV end-systolic volume (ESV) further risk-stratified patients, suggesting that it is a more powerful metric for that purpose.

At present, echocardiography remains the predominant clinically applicable noninvasive test of choice, based on broader availability, whereas alternative modalities, such as radionuclide imaging and cardiac magnetic resonance (CMR), also play an important role, with each modality offering advantages and disadvantages.

**Two-dimensional (2D) and 3-dimensional (3D) echocardiography.** 2D echocardiography is a widely available and well-established means of assessing LV remodeling. This technique can be performed in nearly all patients, including those who are critically ill, and is not associated with any radiation exposure. However, estimates of LV volumes derived from 2D images are subject to variability and error imposed by selection of the imaging plane, inaccuracies in identi-

### ABBREVIATIONS AND ACRONYMS

<b>2D</b>	= 2-dimensional
<b>3D</b>	= 3-dimensional
<b>CMR</b>	= cardiac magnetic resonance
<b>EDV</b>	= end-diastolic volume
<b>ESV</b>	= end-systolic volume
<b>LGE</b>	= late gadolinium enhancement
<b>LV</b>	= left ventricular
<b>LVEF</b>	= left ventricular ejection fraction
<b>LVMI</b>	= left ventricular mass index
<b>MI</b>	= myocardial infarction
<b>RVG</b>	= radionuclide ventriculography
<b>RWT</b>	= relative wall thickness



**Figure 1. MI Size and Subsequent Remodeling**

Patients with larger myocardial infarctions (MI), as reflected by higher serum creatine kinase (CK) levels, show greater 90-day increases in left ventricular end diastolic volume (LVEDV) than patients with smaller MI. Adapted, with permission, from Solomon et al. (57).

fyng the endocardial border, geometric assumptions underlying the volumetric calculations, and beat-to-beat variation in LV volume and function.

Kober et al. (32) demonstrated the accuracy of echocardiographic LV volumes estimates, using the Simpson method when compared with in vitro canine measurements. A number of studies have demonstrated the superior reproducibility of 2D echocardiography over M mode for measuring LV mass in normal subjects (33,34) and those with abnormal LV geometry (35). Subsequently, harmonic imaging (36) and contrast echocardiography (37) have improved 2D echocardiographic image quality.

More recently, real-time 3D echocardiography has emerged as a clinically feasible method for quantifying ventricular volume and mass. 3D echocardiographic quantification of ventricular volumes and ejection fraction can be performed rapidly and avoids the geometric assumptions and problems of image plane position that are associated with 2D echocardiography. 3D echocardiography has superior accuracy and reproducibility for evaluation of ventricular chambers compared with 2D echocardiography, and several studies have observed that 3D echocardiographic assessments of ventricular volumes, mass, and ejection fraction correlate favorably with CMR (38–42).


**Radionuclide ventriculography.** Equilibrium-gated radionuclide ventriculography (RVG) has been used since the 1970s to assess right ventricular and LV function, with studies of ventricular volumes following soon thereafter. Because ventricular volumes are de-

termined by changes in radionuclide counts, the RVG technique is independent of geometric assumptions and does not rely on operator-defined analysis of regional changes in wall motion or thickening throughout the cardiac cycle (30,43). This factor is especially advantageous over other imaging techniques in patients with ischemic cardiomyopathy, multiple wall motion abnormalities, and altered LV geometry. Because the radionuclide-based volumetric estimate integrates information from multiple cardiac cycles, the technique is not subject to error from individual beat-to-beat variation. Gating methodologies are designed to manage moderate cycle-length variability, although extreme variability, as when ventricular response to atrial fibrillation is excessively irregular, may introduce error into volumetric and functional estimates.

Multiple studies have demonstrated adequate reproducibility and low intraobserver and interobserver variability of RVG in estimating LV volumes in both normal subjects and those with heart disease. Studies comparing RVG with both contrast ventriculography (44,45) and visual estimation by 2D echocardiography (46) found that RVG is comparable to these 2 methods in estimating LVEF and has higher reproducibility.

Like any imaging modality, a high-quality, reproducible study is dependent on operator expertise in acquisition and analysis. Although LV volumes may not be routinely reported in many cardiac nuclear medicine laboratories, laboratories with qualified physicians and technologists can be trained to acquire high-quality data, and central data analysis will optimize accuracy and reproducibility of volumetric estimates for clinical trial purposes.

**CMR.** CMR is a 3D imaging technique producing images with high spatial and temporal resolution. The generation of thin, short-axis imaging slices with full ventricular coverage results in truly tomographic imaging without the limitation of geometric assumptions associated with 2D non-tomographic imaging techniques. In addition, contemporary imaging sequences generate sharp contrast between the bright blood pool and dark myocardium, which results in accurate measurements of volume, mass, and wall thickness. A number of investigations have demonstrated strong correlations for LVEFs and volumes measured by CMR versus contrast angiography or echocardiography (47,48). CMR is now considered the reference for noninvasive measurements of functional and volumetric parameters. In addition, the supe-



**Figure 2. Ventricular Remodeling: Gross and Microscopic Architecture**

Schematic representation of post-myocardial infarction (post-MI) left ventricular remodeling. The early phase is characterized by thinning and elongation of the fibrous scar within the infarcted zone. Subsequent left ventricular dilation, with transition from an elliptical to a more spherical configuration, is driven principally by diffuse myocyte hypertrophy associated with increased apoptosis (not shown) and increases in interstitial collagen. Figure illustration by Craig Skaggs.


rior reproducibility of these measurements with CMR facilitates application of CMR as a research tool for clinical investigation. For example, the sample size needed to demonstrate a given change in volume or mass with statistical confidence is substantially reduced with CMR compared with 2D echocardiography, a factor that may offset the increased cost of CMR by virtue of the savings from studying fewer patients per trial (49).

Beyond geometric measurements, contrast-enhanced CMR, with assessment of late gadolinium enhancement (LGE), has demonstrated the ability to predict patient risk of adverse remodeling post-MI (50–52). Due to the high spatial resolution, LGE, a marker of myocardial scarring, can identify acute and chronic MI with high accuracy and reproducibility (53). Areas of LGE can be planimeted, and the amount quantified and expressed as a percentage of the total LV mass or a percentage of the LV wall segment involved (50). This technique can also demonstrate microvascular obstruction, as evidenced by a central dark zone, surrounded by bright enhancement of the infarcted core (54), a finding that marks a greater risk of adverse LV remodeling post-MI.

### Relationship Between LV Remodeling and Prognosis in Patients With Heart Failure and Decreased LVEF

**Relationship between clinical outcomes and cross-sectional LV measurements.** In 1987, White et al. (31) observed that LVEF measured 1 to 2 months after thrombolytic therapy for MI was a powerful

predictor of prognosis, with LV ESV index (ESVi) providing additional predictive value. In a similar population, Migrino et al. (55) demonstrated a continuous relationship between ESVi and both mortality and the development of heart failure symptoms. In a population with symptomatic heart failure and decreased LVEF, Lee et al. (56) found that LV end-diastolic dimension index, measured with M-mode echocardiography, was an independent predictor of survival. In an echocardiographic



**Figure 3. Patterns of Remodeling**

The echocardiographic substudy of the VALIANT (VALsartan In Acute myocardial iNfarction) trial defined 3 patterns of left ventricular (LV) remodeling in patients with heart failure and/or LV ejection fraction  $\leq 35\%$ , based on measurement of left ventricular mass index (LVMI) and relative wall thickness (RWT): concentric remodeling (normal LVMI and increased RWT), eccentric hypertrophy (increased LVMI and normal RWT), concentric hypertrophy (increased LVMI and increased RWT). Reprinted, with permission, from Verma et al. (28).


substudy of the VALIANT (Valsartan in Acute Myocardial Infarction) study, Solomon et al. (57) demonstrated that baseline LVEF, EDV, and ESV were each independent predictors of the primary combined end point of death or heart failure hospitalization (Fig. 4).

Recently, investigators have begun to clarify the differential prognostic implication of different patterns of LV remodeling. In the VALIANT echocardiographic study, Verma et al. (28) found that, compared with patients without evidence of LV remodeling, patients with any of the patterns of LV remodeling post-MI had a greater risk of the composite of cardiovascular death, MI, heart failure, stroke, or resuscitated cardiac arrest. In addition, the patterns of concentric remodeling, eccentric hypertrophy, and concentric hypertrophy were associated with a progressively increased risk of the composite, with each of the individual outcome components following a pattern of risk similar to that of the overall composite (Fig. 5). Thus, although LV volumes remain powerful indicators of cardiovascular prognosis, additional information is contained within the specific pattern of LV remodeling.

These findings point to additional hypotheses related to the nature of the linkage between LV remodeling and cardiovascular events (29). First, the greater adverse implication of concentric hypertrophy suggests that antecedent hypertension of sufficient severity and duration to discernably affect LV structure carries an incremental risk in a patient with subsequent MI. Second, the similarity of risk patterns for subsequent MI and stroke,


compared with that of heart failure and the overall composite end point, suggests that the mechanisms responsible for adverse outcomes are not simply operating through cardiac dysfunction and clinical heart failure. Rather, it is likely that LV remodeling represents a more global biomarker of systemic effects, such as that of hypertension and neurohormonal activation, on the entire cardiovascular system, with a likely association between LV remodeling and vascular changes responsible for coronary and cerebrovascular events.

The extent of LGE by CMR may also represent an important prognostic indicator. The number of LV segments with transmural (i.e., LGE occupying  $\geq 75\%$  of the LV segment) involvement post-MI is predictive of the extent of subsequent LV remodeling, as evidenced by increased LV volumes and decreased LVEF, independent of the magnitude of troponin increase (58). The extent of LGE also predicts the likelihood of functional recovery after either coronary revascularization or medical therapy. Those LV segments without LGE have approximately an 80% chance for improvement in function post-revascularization (52). Similarly, in patients with heart failure and decreased LVEF, systolic performance improved in more than half of LV segments without LGE, but in only rare segments with transmural LGE after 6 months of beta-blocker therapy (59). CMR evidence of microvascular obstruction post-MI predicts a greater likelihood of thinning and lack of functional recovery in a particular myocardial segment and a greater



**Figure 4. Ventricular Measurements and Prognosis**

Relationship between echocardiographic parameters, ejection fraction, end-diastolic volume, and infarct segment length, and the combined outcome of death or hospitalization for heart failure (HF) after myocardial infarction. Reprinted, with permission, from Solomon et al. (57).



**Figure 5. Remodeling Patterns and Cardiovascular Events**

Compared with patients without evidence of left ventricular (LV) remodeling, patients with any of the patterns of LV remodeling post-myocardial infarction (MI) had a greater risk of the composite of cardiovascular (CV) death, MI, heart failure (HF), stroke, or resuscitated cardiac arrest. In addition, the patterns of concentric remodeling, eccentric hypertrophy, and concentric hypertrophy were associated with a progressively increased risk of the composite end point, with each of the individual outcome components following a risk pattern similar to that of the overall composite. SD = sudden death. Reprinted, with permission, from Verma *et al.* (28).


overall likelihood of future adverse cardiovascular events (60).

Although more work is needed in this area, it is likely that the combination of LV geometric indicators, such as volumes and overall patterns of remodeling, along with myocardial characteristics, such as LGE and microvascular obstruction, will together form a powerful constellation of findings predicting subsequent clinical outcomes.

**Relationship between clinical outcomes and longitudinal LV measurements.** A number of studies have supported the value of serial changes in parameters of LV remodeling for predicting clinical outcomes in patients with LV dilation and/or decreased LVEF. Data from the echocardiographic substudy of the SAVE (Studies of Ventricular Enlargement) trial demonstrated that longitudinal changes in LV area >1 year after MI significantly correlated with subsequent long-term rates of cardiovascular events, independent of randomization to either captopril or placebo (Fig. 6) (61). Similarly, echocardiographic data from the Val-HeFT (Valsartan Heart Failure Trial) in 5,010 patients with heart failure and both LVEF <40% and LV end-diastolic dimension index >2.9 cm/m<sup>2</sup>, showed that both baseline LV end-diastolic dimension index and LVEF and changes in these parameters over time were independent predictors of patient outcome (62).

### Relationship Between an Intervention's Effect on Remodeling and its Effect on Clinical Outcomes in Patients with Heart Failure and Decreased LVEF

Beyond mere prognostication, measures of LV remodeling have been used extensively to gauge the effect of drug and device interventions on cardiac structure and function. In a radionuclide ventricular



**Figure 6. Longitudinal Ventricular Dilatation and Prognosis**


Changes in left ventricular (LV) area at end-systole and end-diastole over 1 year in patients after myocardial infarction with baseline left ventricular dysfunction, from the SAVE (Studies of Ventricular Enlargement) trial, compared in patients who sustained versus those who did not sustain adverse cardiovascular (CV) events. Patients experiencing events had a significantly greater increase in areas (i.e., more adverse remodeling) compared with those who had no events. Adapted, with permission, from St. John Sutton *et al.* (61).

function substudy of the SOLVD (Studies of Left Ventricular Dysfunction) trial, we demonstrated differences in serial measures of LV volumes for patients randomized to the angiotensin-converting enzyme inhibitor enalapril versus those randomized to placebo, which paralleled the enalapril effect on all-cause mortality and on heart failure hospitalization. We observed that enalapril prevented or reversed the progressive remodeling process seen in placebo-group patients with an LVEF  $\leq 35\%$ , either with (treatment trial) (14) or without (prevention trial) (15) heart failure symptoms (Fig. 7).

Numerous studies have shown favorable effects on parameters of LV remodeling for drugs that improve clinical outcomes in patients with decreased LVEF and LV dilation, notably angiotensin-converting enzyme inhibitors, beta-blockers, and angiotensin receptor blockers (14,15,18,57,63–69). Conversely, agents with neutral or adverse effects on remodeling, relative to a comparator, have often been found to be associated with neutral or adverse effects on clinical outcomes. Examples include omapatrilat (70,71) and ibopamine (72,73). In a head-to-head comparison of the angiotensin-converting enzyme inhibitor captopril, 150 mg daily, with the angiotensin receptor blocker losartan, 50 mg daily, we found a trend favoring captopril in the 1-year change in LV volumes (18), an effect that presaged the mortality findings in ELITE (Early Versus Late Intervention Trial With Estradiol) II (74). Yu et al. (75) showed that a

decrease in LV ESV of  $\geq 10\%$  after cardiac resynchronization therapy predicted decreased long-term mortality and heart failure events, whereas symptomatic improvement did not. More recently, in separate trials, the vasopressin V2 receptor antagonist tolvaptan was shown to have a neutral effect on both ventricular remodeling and long-term clinical outcomes (27,76). In contrast, in 2001, Bozkurt et al. (77), examining 3-month changes in LVEF, EDV, and ESV, showed a dose-dependent, placebo-controlled reverse remodeling effect over 3 months with etanercept, an inhibitor of tumor necrosis factor- $\alpha$ . Three years later, a much larger, long-term study failed to show any long-term clinical outcome benefit (78). Conversely, we were unable to demonstrate a benefit of the aldosterone receptor blocker eplerenone on LV remodeling in a group of patients with class II and III heart failure and decreased LVEF (25), despite the favorable impact that this class of agent has exerted in select patient populations with heart failure and decreased LVEF (79,80). Nevertheless, it appears that in most, but not all, cases there is concordance between an intervention's effect on LV remodeling and heart failure-related clinical outcomes for patients with reduced LVEF, either post-MI or with chronic heart failure.

Recently, we performed a meta-analysis examining the relationship between drug- or device-induced changes in parameters of LV remodeling and the effects of the same interventions on mortality in



**Figure 7. Angiotensin Converting Enzyme Inhibitor Effects on Ventricular Volumes**


Changes in left ventricular end-diastolic volume over time in asymptomatic (Prevention) and symptomatic (Treatment) patients with decreased left ventricular ejection fraction while randomized to placebo or enalapril, from the SOLVD (Studies of Left Ventricular Dysfunction) trials. During long-term follow-up, patients randomized to placebo demonstrate evidence of progressive increase in left ventricular end-diastolic volume, whereas those randomized to enalapril showed reductions in left ventricular volume. wd = restudy after withdrawal of placebo or enalapril. Adapted, with permission, from Konstam et al. (14,15).

patients with heart failure and decreased LVEF (81). We classified 25 drug or device interventions as having favorable, neutral, or unfavorable effects on survival, estimating the odds ratio for death for each intervention compared with placebo based on large-scale, randomized, controlled outcome trials. We then examined the correlation between these odds ratios and the placebo-corrected change from baseline in LV volumes observed in 88 individual remodeling studies performed with each of these interventions (Fig. 8). We found significant correlations between longer term trial-level therapeutic effects on mortality and short-term trial-level therapeutic effects of a drug or device on LVEF ( $r = -0.51$ ,  $p = <0.001$ ), EDV ( $r = 0.44$ ,  $p = 0.002$ ), and ESV ( $r = 0.48$ ,  $p = 0.002$ ). Furthermore, these drug-/device-induced changes in ventricular remodeling reflect the probability of a categorical mortality outcome (favorable, neutral, or adverse) for those therapies. These findings provide the best support available linking interventional effects on the process of LV remodeling and on clinical outcomes in patients with decreased LVEF and heart failure and suggest that the placebo-corrected effect of a drug or device on the process of

remodeling can serve as a probability signal of that intervention's potential effect on mortality. Certainly, an intervention might exert a favorable effect on clinical outcomes through mechanisms divorced from those responsible for LV remodeling. In the case of aldosterone receptor blockade, we postulate that at least some of the outcome benefit may be mediated through vascular effects. Conversely, off-target adverse effects may offset the clinical benefit derived from a drug's or device's favorable impact on the progression of myocardial pathology. Nevertheless, results of our meta-analysis support the use of remodeling data as a means of selecting agents to seek evidence of outcome benefit through larger scale investigation, focusing on clinical events. Further, although remodeling benefit cannot be taken as a definitive surrogate end point for survival, demonstrable remodeling benefit of a drug or device serves to substantiate and render more credible a survival signal observed with that intervention.

### Conclusions

The process of ventricular remodeling is well established and well described in animal models of LV



**Figure 8. Correlation of an Intervention's Effect on Remodeling and on Mortality**

Quantitative relationship between drug/device effects on ejection fraction (EF), end-diastolic volume (EDV), end-systolic volume (ESV), and mortality in patients with heart failure and left ventricular dysfunction. Each data point represents a placebo-corrected change in EF (A), EDV (B), or ESV (C) from an individual remodeling trial plotted against the mortality odds ratio for the specific therapy. Interventions were classified as favorable if the upper limit of the 95% confidence interval of the odds ratio for death from the mortality trials was  $<1$ , neutral if the confidence interval crossed 1, and adverse if the lower limit of the confidence interval was  $>1$ . There was a significant correlation between longer term therapeutic effect on mortality and short-term therapeutic effect on left ventricular EF ( $r = -0.51$ ,  $p < 0.001$ ), EDV ( $r = 0.44$ ,  $p = 0.002$ ), and ESV ( $r = 0.48$ ,  $p = 0.002$ ). Remodeling data derived from analysis of 86 randomized, controlled trials (RCTs) of 25 interventions, including 19,092 total patients. Reprinted, with permission, from Kramer et al. (81).

stress and injury and in patients after MI and other forms of dilated cardiomyopathy. Various techniques have been developed to explore the remodeling process in patients, each carrying advantages and disadvantages. These techniques have been extensively deployed in clinical trials, demonstrating the value of baseline LV volumes and change in LV dimension, area, and volume over time, for predicting subsequent clinical outcomes. Beyond LV volumes, the pattern of LV remodeling was recently shown to carry additional predictive value for vascular and heart failure-related events. These findings support the hypothesis that the linkage between LV remodeling and outcome occurs not merely through the adverse impact of cardiac pathology per se, but also via the role of LV morpho-

logic change as a measure of concomitant vascular pathology. Finally, our recent meta-analysis correlating drug and device effects on LV volumes and on survival within a given population strengthens our understanding of the impact of remodeling changes on clinical outcomes in heart failure and provides support for the use of remodeling parameters to guide subsequent larger scale clinical investigation and to help substantiate a given outcome signal within a given population.

---

**Reprint requests and correspondence:** Dr. Marvin A. Konstam, Tufts Medical Center, Box 108, 800 Washington Street, Boston, Massachusetts 02111. *E-mail:* [mkonstam@tuftsmedicalcenter.org](mailto:mkonstam@tuftsmedicalcenter.org).

---

## REFERENCES

- Eaton LW, Weiss JL, Bulkley BH, Garrison JB, Weisfeldt ML. Regional cardiac dilatation after acute myocardial infarction: recognition by two-dimensional echocardiography. *N Engl J Med* 1979;300:57-62.
- Erlebacher JA, Weiss JL, Eaton LW, Kallman C, Weisfeldt ML, Bulkley BH. Late effects of acute infarct dilation on heart size: a two dimensional echocardiographic study. *Am J Cardiol* 1982;49:1120-6.
- McKay RG, Pfeffer MA, Pasternak RC, et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. *Circulation* 1986;74:693-702.
- Patten RD, Konstam MA. Ventricular remodeling and the renin angiotensin aldosterone system. *Congest Heart Fail* 2000;6:187-92.
- Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodeling. *Lancet* 2006;367:356-67.
- Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. *Circulation* 1990;81:1161-72.
- Chareonthaitawee P, Christian TF, Hirose K, Gibbons RJ, Rumberger JA. Relation of initial infarct size to extent of left ventricular remodeling in the year after acute myocardial infarction. *J Am Coll Cardiol* 1995;25:567-73.
- van Gilst WH, Kingma JH, Peels KH, Dambrink JH, St. John Sutton M. Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS). *J Am Coll Cardiol* 1996;28:114-21.
- Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study. *Ann Intern Med* 2001;134:451-8.
- Cohen MV, Yang XM, Neumann T, Heusch G, Downey JM. Favorable remodeling enhances recovery of regional myocardial function in the weeks after infarction in ischemically preconditioned hearts. *Circulation* 2000;102:579-83.
- Mitchell GF, Lamas GA, Vaughan DE, Pfeffer MA. Left ventricular remodeling in the year after first anterior myocardial infarction: a quantitative analysis of contractile segment lengths and ventricular shape. *J Am Coll Cardiol* 1992;19:1136-44.
- Douglas PS, Morrow R, Ioli A, Reichek N. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. *J Am Coll Cardiol* 1989;13:311-5.
- Rumberger JA, Behrenbeck T, Breen JR, Reed JE, Gersh BJ. Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infarction in humans. *J Am Coll Cardiol* 1993;21:673-82.
- Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. *Circulation* 1992;86:431-38.
- Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. *Circulation* 1993;88:2277-83.
- Pouleur HG, Konstam MA, Udelson JE, Rousseau MF. Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. The SOLVD Investigators. *J Am Coll Cardiol* 1993; 22 Suppl A:43A-48A.
- Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. *Circulation* 1995;91:2573-81.
- Konstam MA, Patten RD, Thomas I, et al. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. *Am Heart J* 2000;139:1081-7.
- Senior R, Basu S, Kinsey C, Schaeffer S, Lahiri A. Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. *Am Heart J* 1999;137:646-52.
- Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. *Circulation* 1996;94:2800-6.
- Lechat P, Escolano S, Golmard JL, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). *Circulation* 1997;96:2197-205.

22. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. *J Am Coll Cardiol* 2000;36:2072-80.
23. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. *J Am Coll Cardiol* 1995;25:1154-61.
24. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. *J Am Coll Cardiol* 2001;37:1228-33.
25. Udelson JE, Feldman AM, Greenberg B, et al. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. *Circ Heart Fail* 2010;3:347-53.
26. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. *Lancet* 2004;364:347-54.
27. Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. *J Am Coll Cardiol* 2007;49:2151-9.
28. Verma A, Meris A, Skali H, et al. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. *J Am Coll Cardiol* 2008;51:582-91.
29. Konstam MA, Udelson JE, Anand IS, Cohn JN. Ventricular remodeling in heart failure: a credible surrogate endpoint. *J Card Fail* 2003;9:350-3.
30. Anand IS, Florea VG, Solomon SD, Konstam MA, Udelson JE. Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials. *J Card Fail* 2002;8 Suppl:S452-64.
31. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. *Circulation* 1987;76:44-51.
32. Kober L, Torp-Pedersen C, Carlsen J, Videbaek R, Egeblad H. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). *TRAndolapril Cardiac Evaluation*. *Eur Heart J* 1994;15:1616-20.
33. Collins HW, Kronenberg MW, Byrd BF 3rd. Reproducibility of left ventricular mass measurements by two-dimensional and M-mode echocardiography. *J Am Coll Cardiol* 1989;14:672-6.
34. Himelman RB, Cassidy MM, Landzberg JS, Schiller NB. Reproducibility of quantitative two-dimensional echocardiography. *Am Heart J* 1988;115:425-31.
35. Reichek N. Standardization in the measurement of left ventricular wall mass. Two-dimensional echocardiography. *Hypertension* 1987;9:II30-2.
36. Kasprzak JD, Paelinck B, Ten Cate FJ, et al. Comparison of native and contrast-enhanced harmonic echocardiography for visualization of left ventricular endocardial border. *Am J Cardiol* 1999;83:211-7.
37. Mulvagh SL, DeMaria AN, Feinstein SB, et al. Contrast echocardiography: current and future applications. *J Am Soc Echocardiogr* 2000;13:331-42.
38. Jenkins C, Bricknell K, Hanekom L, Marwick TH. Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. *J Am Coll Cardiol* 2004;44:878-86.
39. Takeuchi M, Nishikage T, Mor-Avi V, et al. Measurement of left ventricular mass by real-time three-dimensional echocardiography: validation against magnetic resonance and comparison with two-dimensional and m-mode measurements. *J Am Soc Echocardiogr* 2008;21:1001-5.
40. Sugeng L, Mor-Avi V, Weinert L, et al. Quantitative assessment of left ventricular size and function: side-by-side comparison of real-time three-dimensional echocardiography and computed tomography with magnetic resonance reference. *Circulation* 2006;114:654-61.
41. Nesser HJ, Tkalec W, Patel AR, et al. Quantitation of right ventricular volumes and ejection fraction by three-dimensional echocardiography in patients: comparison with magnetic resonance imaging and radionuclide ventriculography. *Echocardiography* 2006;23:666-80.
42. Sugeng L, Mor-Avi V, Weinert L, et al. Multimodality comparison of quantitative volumetric analysis of the right ventricle. *J Am Coll Cardiol* 2010;3:10-8.
43. Konstam MA, Wynne J, Holman BL, Brown EJ, Neill JM, Kozlowski J. Use of equilibrium (gated) radionuclide ventriculography to quantitate left ventricular output in patients with and without left-sided valvular regurgitation. *Circulation* 1981;64:578-85.
44. Upton MT, Rerych SK, Newman GE, Bounous EP, Jr., Jones RH. The reproducibility of radionuclide angiographic measurements of left ventricular function in normal subjects at rest and during exercise. *Circulation* 1980;62:126-32.
45. Cohn PF, Levine JA, Bergeron GA, Gorlin R. Reproducibility of the angiographic left ventricular ejection fraction in patients with coronary artery disease. *Am Heart J* 1974;88:713-20.
46. van Royen N, Jaffe CC, Krumholz HM, et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. *Am J Cardiol* 1996;77:843-50.
47. Otterstad JE, Froeland G, St. John Sutton M, Holme I. Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. *Eur Heart J* 1997;18:507-13.
48. Bottini PB, Carr AA, Prisant LM, Flickinger FW, Allison JD, Gottdiener JS. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. *Am J Hypertens* 1995;8:221-8.
49. Bellenger NG, Marcus NJ, Rajappan K, Yacoub M, Banner NR, Pennell DJ. Comparison of techniques for the measurement of left ventricular function following cardiac transplantation. *J Cardiovasc Magn Reson* 2002;4:255-63.
50. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. *Circulation* 1999;100:1992-2002.
51. Fieno DS, Kim RJ, Chen EL, Lomasney JW, Klocke FJ, Judd RM. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. *J Am Coll Cardiol* 2000;36:1985-91.
52. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. *N Engl J Med* 2000;343:1445-53.

53. Mahrholdt H, Wagner A, Holly TA, et al. Reproducibility of chronic infarct size measurement by contrast-enhanced magnetic resonance imaging. *Circulation* 2002;106:2322-7.
54. Pennell DJ. Cardiovascular magnetic resonance. *Circulation* 2010;121:692-705.
55. Migrino RQ, Young JB, Ellis SG, et al. End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. *Circulation* 1997;96:116-21.
56. Lee TH, Hamilton MA, Stevenson LW, et al. Impact of left ventricular cavity size on survival in advanced heart failure. *Am J Cardiol* 1993;72:672-6.
57. Solomon SD, Skali H, Anavekar NS, et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. *Circulation* 2005;111:3411-9.
58. Tarantini G, Razzolini R, Cacciavillani L, et al. Influence of transmural-ity, infarct size, and severe microvascular obstruction on left ventricular remodeling and function after primary coronary angioplasty. *Am J Cardiol* 2006;98:1033-40.
59. Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. *Circulation* 2003;108:1945-53.
60. Baks T, van Geuns RJ, Biagini E, et al. Effects of primary angioplasty for acute myocardial infarction on early and late infarct size and left ventricular wall characteristics. *J Am Coll Cardiol* 2006;47:40-4.
61. St. John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. *Circulation* 1994;89:68-75.
62. Wong M, Staszewsky L, Latini R, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. *J Am Coll Cardiol* 2004;43:2022-7.
63. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. *J Am Coll Cardiol* 1997;29:1060-6.
64. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. *Circulation* 1995;91:2573-81.
65. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med* 1992;327:669-77.
66. Wong M, Johnson G, Shabetai R, et al. Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group. *Circulation* 1993;87 Suppl:VI65-70.
67. Wong M, Staszewsky L, Latini R, et al. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. *J Am Coll Cardiol* 2004;43:2022-7.
68. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet* 2003;362:772-6.
69. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. *Lancet* 2003;362:767-71.
70. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). *Circulation* 2002;106:920-6.
71. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. *Lancet* 2000;356:615-20.
72. Rousseau MF, Konstam MA, Benedict CR, et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. *Am J Cardiol* 1994;73:488-93.
73. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. *Lancet* 1997;349:971-7.
74. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. *Lancet* 2000;355:1582-7.
75. Yu CM, Bleeker GB, Fung JW, et al. Left ventricular reverse remodeling but not clinical improvement predicts long-term survival after cardiac resynchronization therapy. *Circulation* 2005;112:1580-6.
76. Konstam MA, Gheorghiadu M, Burnett JC, Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. *JAMA* 2007;297:1319-31.
77. Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted antitumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. *Circulation* 2001;103:1044-7.
78. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). *Circulation* 2004;109:1594-602.
79. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999;341:709-17.
80. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 2003;348:1309-21.
81. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. *J Am Coll Cardiol* 2010;56:392-406.

**Key Words:** cardiac imaging ■ heart failure ■ ventricular remodeling.